TMS for Suicidal Crisis in Active Duty SMs

Suicide Clinical Trial

— TMS4SI  

Official title:

Utility of Repetitive Transcranial Magnetic Stimulation (TMS) in Promoting Rapid Psychiatric Stabilization in Acutely Suicidal Military Service Members

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03014362
• Other study ID #: 1604023
• Status: Completed
• Phase: N/A
• Start date: June 12, 2017
• Est. completion date: September 10, 2021

Study information

• Verified date: September 2022
• Source: Eisenhower Army Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if the use of Transcranial Magnetic Stimulation (TMS) provides rapid reduction and sustained attenuation of suicidal crisis. TMS is a treatment for suicidal crisis that is quicker, less invasive, better tolerated, and with fewer side effects than current treatments such as Electroconvulsive Therapy (ECT) and medication therapies. There will be 6 months of follow-up, in order to establish the ongoing and lasting therapeutic effect of TMS.

Description:

The programmatic-level objective of the study is to address the goals of the Army STARRS Program and the Suicide Prevention for America's Veterans Act through implementation of an effective acute treatment for patients psychiatrically admitted in suicidal crisis as well as other patients at high-risk for suicide. This is achieved by application of TMS, which provides a treatment for suicidal crisis that is quicker, less invasive, better tolerated, and with fewer side effects and less incapacitation than current treatments such as ECT and pharmacologic therapies. A recent study led by the senior consultant of this proposal demonstrated tolerance and efficacy for a new, high-dose regimen of TMS in a VA population with an average age of 47. The objective of the proposed study is to extend the application of TMS to a younger population of Active Duty Service Members (SM) in order to demonstrate efficacy for returning veterans of the Middle East wars, in particular, as well as the civilian young adult population. TMS dosage in the proposed study is recalibrated to commercially-standard levels in order to provide consistency with devices currently in clinical operation. In addition, follow-up in the proposed study continues for 6 months in order to establish persistence and durability of the therapeutic effect of TMS.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: September 10, 2021
• Est. primary completion date: January 10, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• All Active Duty SMs (regardless of sex, ethnicity, sexual or religious orientation) who are admitted to Eisenhower Army Medical Center (EAMC) Inpatient Psychiatric Service (IPS) with active suicidality or elevated risk for suicide regardless of most psychiatric diagnostic co-morbidity (see exclusion criteria). This includes in-patient admissions for suicidality and outpatient SMs with a Columbia-Suicide Severity Rating Scale (C-SSRS) score =3.

• Age 18 to 60

• Able to speak and read English.

Exclusion Criteria:

• Combative with staff.

• Comatose/catatonia.

• Incapacity owing to active mania or psychosis.

• Epilepsy, multiple sclerosis, or cerebrovascular accident.

• Non-removable metal in the head (Shrapnel; plates, aneurysm coils/clips; metal tattoos etc.)

• Implantable devices (pacemakers, stimulators, etc.)

• Schizophrenic or borderline personality.

• Positive screen for pregnancy.

• Already receiving TMS as a treatment for depression.

• Non-English reading and speaking subjects

Related Conditions & MeSH terms

• Self-Injurious Behavior
• Suicidal and Self-Injurious Behavior
• Suicidal Depression
• Suicidal Ideation
• Suicidal Impulses
• Suicidal Intention
• Suicide

Intervention

Device:
• Neuronetics NeuroStar XPLOR magnetic stimulator - Active
Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes. Treatment Dose: ~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC.
• Neuronetics NeuroStar XPLOR magnetic stimulator - Sham
Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC.

Locations

Country	Name	City	State
United States	Eisenhower Army Medical Center	Augusta	Georgia

Sponsors (4)

Lead Sponsor	Collaborator
Eisenhower Army Medical Center	Augusta University, Congressionally Directed Medical Research Programs, The Geneva Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Suicidal Ideation (Acute)	The Beck Scale for Suicidal Ideation (SSI-T) is a 19-item clinician administered scale measuring current suicide ideation (SSI-C), suicide ideation at its worst point in the patient's life (SSI-W), and degree of hopelessness. The scale has been well validated. SSI-T scores range from 0-38, with higher scores indicating greater suicide risk.	Change over the active treatment course ie. the 3 days of active treatment